Evidence map›Paper›PMID 36789266›Full record

ArticleComputational and structural biotechnology journal2023

Semi-automated

Kylie Keijzer, Anne G H Niezink, Janneke W de Boer, Jaap A van Doesum, Walter Noordzij, Tom van Meerten, Lisanne V van Dijk

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Computational and structural biotechnology journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Whole-body CD8Nature communications · 2025
    Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Kylie KeijzerDepartment of Hematology, University Medical Center Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands.
Anne G H NiezinkDepartment of Radiation Oncology, University Medical Center Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands.
Janneke W de BoerDepartment of Hematology, University Medical Center Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands.
Jaap A van DoesumDepartment of Hematology, University Medical Center Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands.
Walter NoordzijDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands.
Tom van MeertenDepartment of Hematology, University Medical Center Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands.
Lisanne V van DijkDepartment of Radiation Oncology, University Medical Center Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands.
University Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the treatment of Non-Hodgkin lymphoma (NHL), multiple therapeutic options are available. Improving outcome predictions are essential to optimize treatment. The metabolic active tumor volume (MATV) has shown to be a prognostic factor in NHL. It is usually retrieved using semi-automated thresholding methods based on standardized uptake values (SUV), calculated from

Indexed as

18F-FDG PETAT, adaptive thresholding methodsCAR, chimeric antigen receptorcc, cubic centimeterCT, computed tomographyDICOM, Digital Imaging and Communications in MedicineDLBCL, Diffuse large B-cell lymphomaEANM, European Association of Nuclear MedicineEARL, EANM Research Ltd.FDG, fluorodeoxyglucoseHL, Hodgkin lymphomaIMG, robustness across image reconstruction methodsIQR, interquartile rangeLBCL, Large B-cell lymphomaLDH, lactate dehydrogenaseMAN, clinician based evaluation using manual segmentationsMATV, Metabolic active tumor volumeMetabolic tumor volumeMIP, Maximum Intensity ProjectionMUST, Multiple SUV ThresholdingNHL, Non-Hodgkin lymphomaNon-Hodgkin lymphomaOBS, robustness across observersOS, overall survivalPD-L1, programmed cell death ligand-1PET, positron emission tomographyPET segmentationPFS, progression free survivalPROG, progression vs non-progressionPTCL, Peripheral T-cell lymphomaPTLD, Post-transplant lymphoproliferative disorderQS, quality scoresSegmentation softwareSOFT, robustness across softwareSUV, standardized uptake valueSUV thresholdingTCL, T-cell lymphomaUMCG, University Medical Center GroningenVOI, volume of interest

Identifiers

PMID36789266
PMCPMC9900370
OpenAlexW4317491807

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.